Clinical Pearls for Subcutaneous Delivery: Optimizing Anti-CD38 Use in Multiple Myeloma
Please visit answersincme.com/860/2026-MC-001665-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ajai Chari, MD; Caitlin Costello, MD; and Beth Faiman, PhD, MSN, APN-BC, TCTCN, AOCN, FAAN, FAPO. In this activity, experts in multiple myeloma (MM) discuss the therapeutic rationale, clinical data, and practical integration of subcutaneous anti-CD38 therapies to optimize care for patients with MM. Upon completion of this activity, participants should be better able to: Recognize the rationale for using subcutaneous (SC) formulations of anti-CD38 monoclonal antibodies in patients with multiple myeloma (MM); Assess the clinical profiles of approved and emerging SC formulations of anti-CD38 monoclonal antibodies in patients with MM; and Outline evidence-based, patient-centered strategies for optimizing outcomes with SC formulations of anti-CD38 monoclonal antibodies in patients with MM.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from CME in Minutes: Education in Oncology & Hematology
Expanding the Use of HER2-Directed ADCs Into Early-Stage Breast Cancer: Multidisciplinary Conversations on (Neo)Adjuvant Care
Personalized Treatment Strategies With First-Line Immunotherapy-Based Regimens in Advanced Colorectal Cancer and Biliary Tract Cancer
KIT D816V in Focus: Optimizing Diagnosis and TKI Therapy in Advanced Systemic Mastocytosis
Cracking the Code of KRAS-Mutant NSCLC: Evidence for Emerging Therapies in First-Line Settings
Get summaries like this every morning.
Free AI-powered recaps of CME in Minutes: Education in Oncology & Hematology and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.